Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Welcome and Introduction to Vi3C

Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer

Impact of Prevention and Screening on Mortality From Five Common Cancers

Cancer Risk Associated With Use of Disease-Modifying Antirheumatic Drugs

Novel Oncolytic Immunotherapy Yields Durable Responses in High-Risk Bladder Cancer

Novel Immunotherapy May Offer Benefit in Early Clinical Trial for Breast Cancer